Cassava Sciences Announces Expansion Of Leadership Team

Cassava Sciences Announces Expansion Of Leadership Team

  • Experienced Attorney Chris Cook Joins Executive Team as General Counsel

  • The new role is expected to be critical to operations and strategic initiatives.

Austin, TX, October 27, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical Alzheimer’s disease biotechnology company, announced the expansion of its executive team with the appointment of Christopher Cook as senior vice president and general counsel. This is a newly created position reporting to President and CEO Remy Barbier.

“Chris is a seasoned lawyer, a seasoned lawyer and a recognized leader in legal matters,” said Remy Barbier. “We are delighted that Chris will soon be joining us as a Senior Advisor to Cassava Sciences. I am confident that his knowledge and rich experience will be a valuable addition to the company’s business operations and strategic initiatives.”

Chris has over 25 years of experience in healthcare, private practice and government. He moved to Cassava Sciences from medical company Alcon, where he has been Head of Litigation and Government Investigations since 2017. Prior to Alcon, he was Vice President and General Counsel for Walmart Central America in San Jose, Costa Rica. Chris practiced law for seventeen years at the multinational law firm Jones Day, where he was a litigation partner in the firm’s Washington, D.C., and Chicago offices. Prior to Jones Day, Chris worked as an Assistant US Attorney in Chicago. He holds a BA in English from Emory University and a Juris Doctor from Harvard Law School.

Phase 3 Clinical Program
Cassava Sciences’ current Phase 3 program consists of two double-blind, randomized, placebo-controlled trials of simufilam, an oral drug that is being studied in approximately 1,750 patients with mild to moderate Alzheimer’s disease. Both Phase 3 studies have been assessed under a specific protocol (SPA) by the US Food and Drug Administration. For more information about Cassava Sciences’ Phase 3 trials, visit ClinicalTrials.gov.

See also  Exploring the Fascinating World of Sciences

 

About Simufilum
Simufilam is a proprietary small molecule (oral) drug from Cassava Sciences that restores the normal form and function of the modified filamin A (FLNA) protein in the brain. Cassava Sciences owns the global development and commercial rights to Alzheimer’s disease research programs and related technologies without any licensing obligations to third parties.

Cassava Science, Inc. about
Cassava Science, Inc. is a clinical stage biotechnology company based in Austin, Texas. Our mission is to identify and treat neurodegenerative diseases such as Alzheimer’s disease. Our new science is based on stabilizing but eliminating an important brain protein. For more information visit: https://www.CassavaSciences.com.

For more information please contact:
Eric Schon, CFO
(512) 501-2450
echoen@CassavaSciences.com

We discuss an incredible interview with Hilary Metz of Cassava Science |: Small Cap Equity Investing

Leave a Comment